Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2001

View Archived Issues

Xenerex and Peregrine establish collaboration for solid tumor antibody therapies

Samaritan and Georgetown enter research collaboration

Molecules with antiangiogenic activity discovered by AEterna

Deoxyspergualin analogue is effective in animal models of graft rejection and lupus

Antizol for methanol poisoning granted orphan drug status in E.C., priority review in Canada

FDA grants CytRx's Flocor fast track status

Celera Genomics to acquire AxyS

Diovan sNDA for heart failure receives priority review by FDA

rhEndostatin successfully completes phase I clinical evaluation

RegeneRx focuses on thymosin beta 4 for chronic wound treatment

Phase I/II clinical testing begins of VLTS-589 for peripheral arterial disease

New low-dose triphasic oral contraceptive from Organon now available in U.S.

CIPF obtains rights to antigen delivery technology for anticancer, antiinfectious applications

Lilly compound reduces fracture risk, increases bone strength in postmenopausal osteoporosis

Advanced Magnetics seeks FDA approval to begin clinical evaluation of iron replacement therapy

Bayer presents pipeline overview at Goldman Sachs Healthcare Conference

Two Novuspharma compounds advance to phase II for gastric cancer

HemispheRx Biopharma commences new clinical studies of Ampligen in multidrug-resistant HIV

Atacand/Zestril combination trial begins

FDA extends BLA action date for Lilly's drotrecogin alfa, new brand name accepted

Mutant HLA class I molecules as novel approach to xenotransplantation and bone marrow transplant

3-DP receives NIH funding

Protein for breast cancer diagnostic/prognostic and staging information available for licensing

6-MNA prodrugs with nabumetone-like antiinflammatory activity

p38 MAP kinase inhibitors and their use described by Novartis team

New Na+/H+ exchange inhibitors particularly useful in cardiac ischemia

Tanabe Seiyaku presents small-molecule cell adhesion inhibitors

Antibacterial and antiprotozoal hygromycin-related compounds in development at Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...